Please sign in to follow a disease.
Text messages may help young adults drink less to cope with stress
NCT ID NCT05074030
First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 3 times
Summary
This study tested a program that combines personalized feedback with text messages to help young adults (ages 18-25) who drink to cope with anxiety or depression. Participants were in a psychiatric partial hospitalization program and drank heavily. The program aimed to reduce drinking and improve coping. The study involved 60 people and compared the new program to a simpler feedback-only approach.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- personalized feedback and text-message intervention
- What this could lead to
- If it works, this could offer a practical, low-cost way to help young adults reduce harmful drinking and cope better with negative emotions.
- What could go wrong
- This is a small, early-stage study with only 60 participants, so results may not apply widely. The intervention is behavioral, so effects may be modest or short-lived.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 25 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. between 18 and 25 years of age 2. reported alcohol use at least 3x weekly over past month and at least one day per week, on average, of binge drinking (as defined as 4+ drinks/2 hours for men and 3+ drinks/2 hours for women) 3. self-reported use of coping motive (mean of 2+ on coping subscale of MDMQ-R, indicating they drink to cope at least "some of the time") 4. current anxiety and/or depression symptomatology (as assessed CES-D scores above cut-off for high risk for clinical depression and GAD-7 scores above cut-off for moderate to severe anxiety) 5. owns a smartphone capable of downloading EMA app. Exclusion Criteria: 1. current DSM-5 diagnosis of moderate/severe substance use disorder (other than alcohol, cannabis, or nicotine) as assessed by research staff via SCID 2. a history of psychotic disorder or current psychotic symptoms as assessed by research staff via SCID 3. current suicidal/homicidal ideation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alcohol use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Butler Hospital
Providence, Rhode Island, 02906, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Brain-Training games rewire the mind to fight alcohol addiction?
- Can a Stress-Hormone blocker take the edge off alcohol?
- Can MDMA plus therapy help veterans fight both PTSD and alcohol addiction?
- Brain scans probe opioid receptor imbalance in alcohol use disorder
- Spinal taps open a window on alcohol use disorder
- Can a natural alcohol byproduct calm withdrawal? hospital trial tests IV acetate